Protara Therapeutics Inc. (TARA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Protara Therapeutics Inc. (TARA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.62

-0.41 (-8.15%)

At close: Jan 15, 2025, 3:02 PM

undefined% (undefined)

Bid	4.6
Market Cap	158.39M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.64
PE Ratio (ttm)	-1.75
Forward PE	n/a
Analyst	Buy

Ask	4.63
Volume	442,692
Avg. Volume (20D)	2,399,149
Open	5.03
Previous Close	5.03
Day's Range	4.57 - 5.20
52-Week Range	1.59 - 10.48
Beta	undefined

About TARA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failur...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 22, 2014

Employees 26

Stock Exchange NASDAQ

Ticker Symbol TARA

Website https://www.protaratx.com

Analyst Forecast

According to 3 analyst ratings, the average rating for TARA stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 398.37% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

+70.06%

Protare Therapeutics shares are trading higher aft... Unlock content with Pro Subscription

News

1 month ago · seekingalpha.com

Protara Therapeutics: Rising From The Ashes

Protara Therapeutics' TARA-002 showed promising Phase 2 results, significantly improving its valuation and offering a strong risk-reward setup despite recent stock fluctuations. The company raised $10...

1 month ago · seekingalpha.com

Protara Therapeutics: Carving New Roads In Bladder Cancer

Protara Therapeutics' TARA-002 shows promising early data in bladder cancer, with a 72% complete response rate at 6 months in a small phase 2 trial. Financially, TARA has 7-8 quarters of funds, potent...

1 month ago · seekingalpha.com

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Initial data from the phase 2 ADVANCED-2 study, using TARA-002 for the treatment of patients with non-muscle invasive bladder cancer, is expected by mid-2025. The global bladder cancer market size is ...

1 month ago · zacks.com

TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy

Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.

1 month ago · benzinga.com

Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?

On Thursday, Protara Therapeutics Inc. TARA stock traded higher after the company revealed results from its ongoing Phase 2 open-label ADVANCED-2 trial.